You are now leaving the Evive Biotech website. Evive offers links to other third party websites that may be of interest to our website visitors. When you click on these links you will leave the Evive’s website and will be redirected to another site. These sites are not under the control of Evive Biotech. Click Continue to proceed or Cancel to go back.

Oct 22, 2019

Evive Receives Orphan-Drug Designation from the U.S. FDA for F-652 for the Treatment of Acute Graft vs Host Disease

Evive Receives Orphan-Drug Designation from the U.S. FDA for F-652 for the Treatment of Acute Graft vs Host Disease

You are now leaving the Evive Biotech website. Evive offers links to other third party websites that may be of interest to our website visitors. When you click on these links you will leave the Evive’s website and will be redirected to another site. These sites are not under the control of Evive Biotech. Click Continue to proceed or Cancel to go back.

X
Share to WeChat